ImageneBio files Inmagene pre-merger financials: $13.7M loss, going concern, $6M cash

ImageneBio, Inc.

Inmagene net loss of $7.6M in Q2 2025 and $13.7M in first half 2025; accumulated deficit $197.5M.
Cash and equivalents $6.0M at June 30, 2025; operating cash burn $19.1M in first half 2025.
Management states substantial doubt about continuing as a going concern; cash insufficient for next 12 months.
Term loan of $22.9M (6% interest, secured by IMG-007) automatically forgiven upon merger close July 25, 2025.
Ikena concurrent financing of $75M contributed to fund IMG-007 development after merger.

item 2.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.